[go: up one dir, main page]

UY26470A1 - 4-piridinil - n - acil - fenilalaninas - Google Patents

4-piridinil - n - acil - fenilalaninas

Info

Publication number
UY26470A1
UY26470A1 UY26470A UY26470A UY26470A1 UY 26470 A1 UY26470 A1 UY 26470A1 UY 26470 A UY26470 A UY 26470A UY 26470 A UY26470 A UY 26470A UY 26470 A1 UY26470 A1 UY 26470A1
Authority
UY
Uruguay
Prior art keywords
phenylalanins
piridinyl
acyl
vcam
vla
Prior art date
Application number
UY26470A
Other languages
English (en)
Inventor
Achyutharao Sidduri
Gerald Lewis Kaplan
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of UY26470A1 publication Critical patent/UY26470A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen compuestos de la fórmula I en los que de R1a R7 tienen las definiciones descritas en la especificación; dichos compuestos son inhibidores de la unión entre la molécula VCAM-1 y las células de expresión del antígeno VLA-4 y, por consiguiente, son útiles para el tratamiento de enfermedades cuyos síntomas y/o lesiones pueden atribuirse a la unión de la molecular VCAM-1 con las células de expresión del VLA- 4.
UY26470A 1999-12-06 2000-12-05 4-piridinil - n - acil - fenilalaninas UY26470A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16909099P 1999-12-06 1999-12-06

Publications (1)

Publication Number Publication Date
UY26470A1 true UY26470A1 (es) 2001-05-31

Family

ID=22614226

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26470A UY26470A1 (es) 1999-12-06 2000-12-05 4-piridinil - n - acil - fenilalaninas

Country Status (33)

Country Link
EP (1) EP1244625B1 (es)
JP (2) JP2003516392A (es)
KR (1) KR100492111B1 (es)
CN (1) CN1196682C (es)
AR (1) AR031083A1 (es)
AT (1) ATE297895T1 (es)
AU (1) AU779063B2 (es)
BR (1) BR0016172A (es)
CA (1) CA2392566A1 (es)
CO (1) CO5080771A1 (es)
CZ (1) CZ20022352A3 (es)
DE (1) DE60020883T2 (es)
DK (1) DK1244625T3 (es)
ES (1) ES2243335T3 (es)
GC (1) GC0000214A (es)
HR (1) HRP20020467A2 (es)
HU (1) HUP0203735A3 (es)
IL (2) IL149622A0 (es)
JO (1) JO2281B1 (es)
MA (1) MA26849A1 (es)
MX (1) MXPA02005240A (es)
MY (1) MY128003A (es)
NO (1) NO322910B1 (es)
NZ (1) NZ518888A (es)
PE (1) PE20010960A1 (es)
PL (1) PL364814A1 (es)
PT (1) PT1244625E (es)
RU (1) RU2270193C2 (es)
TW (1) TWI276629B (es)
UY (1) UY26470A1 (es)
WO (1) WO2001042215A1 (es)
YU (1) YU40502A (es)
ZA (1) ZA200203762B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960597B2 (en) 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
RU2286340C2 (ru) 2000-08-18 2006-10-27 Адзиномото Ко., Инк. Новые производные фенилаланина
WO2002028830A1 (en) * 2000-09-29 2002-04-11 Ajinomoto Co.,Inc. Novel phenylalanine derivatives
WO2003053926A1 (en) 2001-12-13 2003-07-03 Ajinomoto Co.,Inc. Novel phenylalanine derivative
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
EP1700850B1 (en) 2003-12-22 2015-07-15 Ajinomoto Co., Inc. Phenylalanine derivative
US7618981B2 (en) * 2004-05-06 2009-11-17 Cytokinetics, Inc. Imidazopyridinyl-benzamide anti-cancer agents
WO2006023396A2 (en) * 2004-08-16 2006-03-02 Merck & Co., Inc. Vla-4 antagonists
JP4784224B2 (ja) 2004-09-24 2011-10-05 味の素株式会社 糖鎖転移方法および糖鎖転移酵素
WO2007100763A2 (en) * 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
AR060901A1 (es) * 2006-05-12 2008-07-23 Jerini Ag Compuestos heterociclicos para la inhibicion de integrinas y uso de estos
EP2510941A3 (en) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
PL2288715T3 (pl) 2008-04-11 2015-03-31 Merrimack Pharmaceuticals Inc Łączniki będące albuminą surowicy ludzkiej i ich koniugaty
RU2012106074A (ru) * 2009-07-23 2013-08-27 Байер Кропсайенс Аг Новые алкоксиеноны и енаминокетоны и способ их получения
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
JP6159740B2 (ja) * 2012-01-27 2017-07-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｖｌａ−４を発現する細胞への標的化送達のためのインテグリンアンタゴニスト結合体
BR112015031040A8 (pt) * 2013-06-11 2018-01-02 Receptos Inc Novos moduladores do receptor de glp-1
JP6820282B2 (ja) 2016-02-05 2021-01-27 Ｅａファーマ株式会社 スルホンアミド誘導体及びそれを含有する医薬組成物
ES3003232T3 (en) 2018-10-30 2025-03-10 Gilead Sciences Inc Compounds for inhibition of alpha4beta7 integrin
EP3873900B1 (en) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
CN112969687B (zh) 2018-10-30 2024-08-23 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA848275B (en) * 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
AU726585B2 (en) * 1997-05-29 2000-11-09 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) * 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) * 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
WO1999043642A1 (en) * 1998-02-26 1999-09-02 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
GB9811159D0 (en) * 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
ES2220140T3 (es) * 1998-12-22 2004-12-01 Tanabe Seiyaku Co., Ltd. Inhibidores de la adhesion mediada de celulas por alfa 4 beta 1 (a4b1).
HK1045495A1 (zh) * 1999-01-22 2002-11-29 依兰制药公司 抑制vla-4介导的白细胞粘着的多环化合物

Also Published As

Publication number Publication date
HRP20020467A2 (en) 2004-04-30
JP2008094842A (ja) 2008-04-24
YU40502A (sh) 2005-03-15
CN1196682C (zh) 2005-04-13
GC0000214A (en) 2006-03-29
WO2001042215A1 (en) 2001-06-14
CN1402709A (zh) 2003-03-12
CZ20022352A3 (cs) 2003-05-14
TWI276629B (en) 2007-03-21
KR20020060256A (ko) 2002-07-16
BR0016172A (pt) 2002-08-20
MXPA02005240A (es) 2002-11-07
EP1244625B1 (en) 2005-06-15
KR100492111B1 (ko) 2005-06-01
RU2270193C2 (ru) 2006-02-20
AU2163901A (en) 2001-06-18
JO2281B1 (en) 2005-09-12
PT1244625E (pt) 2005-09-30
ATE297895T1 (de) 2005-07-15
CO5080771A1 (es) 2001-09-25
DK1244625T3 (da) 2005-10-10
HUP0203735A2 (hu) 2003-03-28
AU779063B2 (en) 2005-01-06
DE60020883D1 (de) 2005-07-21
AR031083A1 (es) 2003-09-10
NO20022650L (no) 2002-06-05
NZ518888A (en) 2004-02-27
NO322910B1 (no) 2006-12-18
HK1053470A1 (en) 2003-10-24
JP2003516392A (ja) 2003-05-13
CA2392566A1 (en) 2001-06-14
HUP0203735A3 (en) 2005-03-29
NO20022650D0 (no) 2002-06-05
IL149622A (en) 2006-12-10
MY128003A (en) 2007-01-31
IL149622A0 (en) 2002-11-10
DE60020883T2 (de) 2006-03-23
MA26849A1 (fr) 2004-12-20
EP1244625A1 (en) 2002-10-02
PL364814A1 (en) 2004-12-13
ES2243335T3 (es) 2005-12-01
PE20010960A1 (es) 2001-09-22
ZA200203762B (en) 2004-01-28

Similar Documents

Publication Publication Date Title
UY26470A1 (es) 4-piridinil - n - acil - fenilalaninas
BR0016195A (pt) 4-pirimidinil-n-acil-l-fenilalaninas
UY27169A1 (es) Derivados del ácido isoftálico como inhibidores de metalproteinasas de la matriz
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
CR6939A (es) Polimorfo de monohidrato de zopolrestat
PA8544901A1 (es) Derivados de oxazol
NO2016007I2 (no) Susoktokog
TR200000481T2 (tr) N-Alkonoilfenilalenin türevleri.
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
HN1999000099A (es) Inhibidores no peptidilicos de la union a las celulas dependientes de vla- 4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias.
CY1109732T1 (el) Χρησις παραγωγων βενζο-συνενωμενου ετεροκυκλο σουλφαμιδιου δια την θεραπειαν πονου
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
CR8207A (es) Un conjugado citotoxico ca6 antigeno- especifico y metodos para utilizar el mismo
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
MX9606744A (es) Acidos hidroxamicos sustituidos por sulfonamido arilico como inhibidores de metaloproteinasa de matriz.
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
CO6241131A2 (es) Vacuna
CO2023001681A2 (es) Bancos de células t específicas para antígeno universal y métodos para producir y usar los mismos terapéuticamente
ES2169886T3 (es) Derivados condensados de la piperidina como inhibidor de sintesis de monoxido de nitrogeno.
DK0804465T3 (da) Nye elastaseinhibitorer
AR023546A1 (es) Disulfuros ciclicos de pirrolidincarbonilamina
BR0008368A (pt) Derivados fenilalaninol
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
EP4217403A4 (en) FIBRONECTIN EXTREMA DOMAIN B (EDB)-SPECIFIC CAR-T FOR CANCER
ECSP003805A (es) 4-piridinil-n-acil-l-fenilalaninas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20120530